The efficacy of HPV 16/18 vaccines on sexually active 18–23 year old women and the impact of HPV vaccination on organized cervical cancer screening

References

• Schiffman MH, Bauer HM, Hoover RN, Glass G, Cadell DM, Rush BB, et al. Epidemiologic evidence showing that human papillomavirus infection causes most cervical intraepithelial neoplasia. J Natl Cancer Inst. 1993; 85: 958–64
   PubMed Web of Science ®Google Scholar
• Bosch FX, Lorincz A, Munoz N, Meijer CJ, Shah KV. The causal relation between human papillomavirus and cervical cancer. J Clin Pathol. 2002; 55: 244–65
   PubMed Web of Science ®Google Scholar
• Tjalma WAA, Arbyn M, Paavonen J, Van Waes TR, Bogers JJ. Prophylactic human papillomavirus vaccines: the beginning of the end of cervical cancer. Int J Gynecol Cancer. 2004; 14: 751–61
   PubMed Web of Science ®Google Scholar
• Baseman JG, Koutsky LA. The epidemiology of human papillomavirus infections. Review. J Clin Virol. 2005; 32S: 16–24
   Web of Science ®Google Scholar
• Schiffman M, Castle PE. Human papillomavirus: epidemiology and public health. Arch Pathol Lab Med. 2003; 127: 930–4
   PubMed Web of Science ®Google Scholar
• Schiffman M, Kjaer SK. Chapter 2: natural history of anogenital human papillomavirus infection and neoplasia. J Natl Cancer Inst Monogr. 2003; 31: 14–9
   PubMedGoogle Scholar
• Harper DM, Franco EL, Wheeler CM, Moscicki AB, Romanowski B, Roteli-Martins CM, et al. Sustained efficacy up to 4–5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet. 2006; 367: 1247–55
   PubMed Web of Science ®Google Scholar
• The FUTURE II Study Group. Quadrivalent HPV vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med. 2007;356:1915–27.
   PubMed Web of Science ®Google Scholar
• Collins S, Mazloomzadeh S, Winter H, Blomfield P, Bailey A, Young LS, et al. High incidence of cervical human papillomavirus infection in women during their first sexual relationship. BJOG. 2002; 109: 96–8
   PubMed Web of Science ®Google Scholar
• ACOG Practice Bulletin. Cervical cytology screening. Int J Gynaecol Obstet. 2003;83:237–47.
   PubMed Web of Science ®Google Scholar
• Richart RM. Cervical intraepithelial neoplasia. Patholo Annu, SC Sommers, 1973; 301–28
   Google Scholar
• Sigurdsson K. Trends in cervical intra-epithelial neoplasia in Iceland through 1995: evaluation of targeted age groups and screening intervals. Acta Obstet Gynecol Scand. 1999;78:486–92.
   PubMed Web of Science ®Google Scholar
• Sigurdsson K, Sigvaldason H. Is it rational to start population-based cervical cancer screening at or soon after age 20? Analysis of time trends in preinvasive and invasive disease. Eur J Cancer. 2007; 43: 769–74
   PubMed Web of Science ®Google Scholar
• Sigurdsson K, Sigvaldason H. Effectiveness of cervical cancer screening in Iceland, 1964–2002: a study on trends in incidence and mortality and the effect of risk factors. Acta Obstet Gynecol Scand. 2006; 85: 343–9
   PubMed Web of Science ®Google Scholar
• Sigurdsson K, Taddeo FJ, Benediktsdottir KR, Olafsdottir K, Sigvaldason H, Oddsson K, et al. HPV genotypes in CIN 2-3 lesions and cancer. A population-based study. Int J Cancer. 2007; 121: 2682–7
   PubMed Web of Science ®Google Scholar
• Gudmundsdottir Th, Tryggvadottir L, Allende M, Mast TC, Briem H, Sigurdsson K. Eligibility and willingness of young Icelandic women to participate in a HPV vaccination trial. Acta Obstet Gynecol Scand. 2003;82:345–50.
   PubMed Web of Science ®Google Scholar
• Villa LL, Costa RL, Petta CA, Andrade RP, Paavonen J, Iversen OE, et al. High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up. Br J Cancer. 2006; 95(11)1459–66
   PubMed Web of Science ®Google Scholar
• Armitage P. Trend in proportions. Statistical methods in medical research. London: Blackwell Scientific Publication, 1971; 362–4.
   Google Scholar
• Gebski V, Leung O, McNeil D, Linn D SPIDA User's Manual, 6th ed. New South WalesAustralia: Statistical Computing Laboratory, Macquarie University, 1992.
   Google Scholar
• Shingleton HM, Orr JW. Historical aspects, pathogenesis and epidemiology. Cancer of the cervix. Philadelphia: J. B. Lippincott Company, 1995; 1–15.
   Google Scholar
• IARC. Cervical cancer and screening. IARC Handbooks of cancer prevention, vol. 10. Lyon: IARC press, 2005; 1–57.
   Google Scholar
• Sigurdsson K. The Icelandic and Nordic cervical screening programs: trends in incidence and mortality rates through 1995. Acta Obstet Gynecol Scand. 1999; 78: 478–85
   PubMed Web of Science ®Google Scholar
• Sigurdsson K. Cervical cancer screening effectiveness and implications of HPV vaccines. European Magazine on Sexual and Reproductive Health-Entre Nous-WHO publication. 2007; 64: 16–18
   Google Scholar
• Laukkanen P, Koskela P, Pukkala E, Dillner J, Läärä E, Knekt P, Lehtinen M, et al. Time trends in incidence and prevalence of human papillomavirus type 6, 11 and 16 infections in Finland. J Gen Virol. 2003; 84: 2105–9
   PubMed Web of Science ®Google Scholar
• Brown RB, Kjaer SK, Sigurdsson K, Iversen O-E, Hernandez-Avila M, Wheeler CM, , et al. The impact of quadrivalent HPV (type 6/11/16/18) L1 VLP vaccine: on infection and disease due to oncogenic non-vaccine HPV types in generally HPV naïve women aged 16–26. JID. September, 2008, in press.
   Google Scholar
• The Future II Study Group. Prophylactic efficacy of a quadrivalent human papillomavirus (HPV) vaccine in women with virological evidence of HPV infection. JID. 2007;196:1438–46.
   Google Scholar
• Baden RB, Curfman GD, Morrissey S, Drazen JM. Human papillomavirus vaccine-opportunity and challenge. Editorials. N Engl J Med. 2007; 356: 1990–3
   PubMed Web of Science ®Google Scholar
• Hildesheim A, Herrero R. Human papillomavirus vaccine should be given before sexual debut for maximum benefit. JID. 2007; 196: 1431–2
   PubMed Web of Science ®Google Scholar
• Kim JJ. Human papillomavirus vaccination in the UK. Is projected to be beneficial and cost effective. BMJ. 2008; 337: 303–4
   Google Scholar
• Kjær SK, Tran TN, Sparen P, Tryggvadottir L, Munk C, Dasbach E, et al. The burden of genital warts: a study of nearly 70,000 women from the general female population in the 4 Nordic countries. JID. 2007; 196: 1447–54
   PubMed Web of Science ®Google Scholar
• Kulasingam SL, Myers ER. Potential health and economic impact of adding a human papillomavirus vaccine to screening programs. JAMA. 2003; 290: 781–9
   PubMed Web of Science ®Google Scholar
• Goldie SJ, Kohli M, Grima D, Weinstein MC, Wright TC, Bosch FX, Franco E, et al. Projected clinical benefits and cost-effectiveness of a human papillomavirus 16/18 vaccine. J Natl Cancer Inst. 2004; 96: 604–15
   PubMed Web of Science ®Google Scholar
• Luostarinen T, af Geijerstam V, Björge T, Eklund C, Hakama M, Hakulinen T. No excess risk of cervical carcinoma among women seropositive for both HPV 16 and HPV 6/11. Int J Cancer. 1999; 80: 818–22
   PubMed Web of Science ®Google Scholar